PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
CA-125 KELIM as a tool to identify which patients can benefit from PARPi in high grade serous advanced ovarian cancer: A retrospective diagnostic accuracy study.
Version 1
: Received: 31 March 2024 / Approved: 1 April 2024 / Online: 1 April 2024 (11:12:26 CEST)
How to cite:
Zouzoulas, D.; Tsolakidis, D.; Tzitzis, P.; Chatzistamatiou, K.; Theodoulidis, V.; Sofianou, I.; Grimbizis, G.; Timotheadou, E. CA-125 KELIM as a tool to identify which patients can benefit from PARPi in high grade serous advanced ovarian cancer: A retrospective diagnostic accuracy study.. Preprints2024, 2024040043. https://doi.org/10.20944/preprints202404.0043.v1
Zouzoulas, D.; Tsolakidis, D.; Tzitzis, P.; Chatzistamatiou, K.; Theodoulidis, V.; Sofianou, I.; Grimbizis, G.; Timotheadou, E. CA-125 KELIM as a tool to identify which patients can benefit from PARPi in high grade serous advanced ovarian cancer: A retrospective diagnostic accuracy study.. Preprints 2024, 2024040043. https://doi.org/10.20944/preprints202404.0043.v1
Zouzoulas, D.; Tsolakidis, D.; Tzitzis, P.; Chatzistamatiou, K.; Theodoulidis, V.; Sofianou, I.; Grimbizis, G.; Timotheadou, E. CA-125 KELIM as a tool to identify which patients can benefit from PARPi in high grade serous advanced ovarian cancer: A retrospective diagnostic accuracy study.. Preprints2024, 2024040043. https://doi.org/10.20944/preprints202404.0043.v1
APA Style
Zouzoulas, D., Tsolakidis, D., Tzitzis, P., Chatzistamatiou, K., Theodoulidis, V., Sofianou, I., Grimbizis, G., & Timotheadou, E. (2024). CA-125 KELIM as a tool to identify which patients can benefit from PARPi in high grade serous advanced ovarian cancer: A retrospective diagnostic accuracy study.. Preprints. https://doi.org/10.20944/preprints202404.0043.v1
Chicago/Turabian Style
Zouzoulas, D., Grigoris Grimbizis and Eleni Timotheadou. 2024 "CA-125 KELIM as a tool to identify which patients can benefit from PARPi in high grade serous advanced ovarian cancer: A retrospective diagnostic accuracy study." Preprints. https://doi.org/10.20944/preprints202404.0043.v1
Abstract
(1) Background: BRCA mutation and homologous recombination deficiency (HRD) are used to administrate PARP inhibitors (PARPi) maintenance therapy. It is known that PARPi efficacy is related to platinum sensitivity and that the latter can be demonstrated from the CA-125 elimination rate constant (KELIM). This study aims to investigate if KELIM can be another tool in the identification of patients that could be benefit from PARPi therapy.; (2) Methods: Retrospective analysis of patients with high-grade serous advanced ovarian cancer that underwent cytoreduction and was further tested for HRD status. The HRD status was tested either by myChoice HRD CDx assay or by RediScore assay. KELIM score was measured in both neoadjuvant and adjuvant settings with the online tool biomarker-kinetics.org.; (3) Results: Thirty-nine patients had available data for estimating both HRD status and KELIM score. When assuming KELIM as a binary index test with the value 1 as the cut-off point, the sensitivity was 0.86, 95% CI (0.64-0.97), and the specificity 0.83, 95% CI (0.59-0.96). On the other hand, when assuming KELIM as a continuous index test, the AUC was 81% and the optimal threshold, using the Youden index, was identified as 1.03 with a sensitivity of 85.7% and a specificity of 83.3%; (4) Conclusions: KELIM score seems to be a new, cheaper and faster tool to identify patients that can benefit from PARPi maintenance therapy.
Medicine and Pharmacology, Obstetrics and Gynaecology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
